These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10976450)

  • 1. [Model and inference for quantal response pharmacological assay].
    Kawai N; Goto M
    Nihon Yakurigaku Zasshi; 2000 Jul; 116(1):29-35. PubMed ID: 10976450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The analysis of dose-response curve from bioassays with quantal response: Deterministic or statistical approaches?
    Mougabure-Cueto G; Sfara V
    Toxicol Lett; 2016 Apr; 248():46-51. PubMed ID: 26952004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An augmented probit model for missing predictable covariates in quantal bioassay with small sample size.
    Follmann D; Nason M
    Biometrics; 2011 Sep; 67(3):1127-34. PubMed ID: 21210769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of outlier tests for potency bioassays.
    Sondag P; Zeng L; Yu B; Yang H; Novick S
    Pharm Stat; 2020 May; 19(3):230-242. PubMed ID: 31762118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of multivariate parallel-line bioassay with composite responses and composite doses, using canonical correlations.
    Yuan W; Kshirsagar AM
    J Biopharm Stat; 1993 Mar; 3(1):57-71. PubMed ID: 8485536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantal bioassay and stroke.
    Zivin JA; Waud DR
    Stroke; 1992 May; 23(5):767-73. PubMed ID: 1579976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models.
    Vølund A
    Biometrics; 1978 Sep; 34(3):357-65. PubMed ID: 719119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical inferences on nonconstant relative potency with quantal response data.
    Kerns LX
    Biom J; 2021 Apr; 63(4):825-840. PubMed ID: 33410246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a statistical outlier in potency bioassays.
    Sondag P; Zeng L; Yu B; Rousseau R; Boulanger B; Yang H; Novick S
    Pharm Stat; 2018 Nov; 17(6):701-709. PubMed ID: 30112804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian analysis of quantal bioassay experiments incorporating historical controls via Bayes factors.
    León Novelo LG; Womack A; Zhu H; Wu X
    Stat Med; 2017 May; 36(12):1907-1923. PubMed ID: 28106916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallelism in practice: approaches to parallelism in bioassays.
    Fleetwood K; Bursa F; Yellowlees A
    PDA J Pharm Sci Technol; 2015; 69(2):248-63. PubMed ID: 25868991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian approach to the analysis of quantal bioassay studies using nonparametric mixture models.
    Fronczyk K; Kottas A
    Biometrics; 2014 Mar; 70(1):95-102. PubMed ID: 24354490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A curve similarity approach to parallelism testing in bioassay.
    Faya P; Rauk AP; Griffiths KL; Parekh B
    J Biopharm Stat; 2020 Jul; 30(4):721-733. PubMed ID: 32163316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive new in vitro bioassay for melanocyte-stimulating activity using the skin of Anolis carolinensis.
    Carter RJ; Shuster S
    J Invest Dermatol; 1978 Oct; 71(4):229-32. PubMed ID: 212484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Method for Qualification of a Potency Assay through Partial Computer Simulation.
    Novick S; Sondag P; Schofield T; Miller K
    PDA J Pharm Sci Technol; 2018; 72(3):249-263. PubMed ID: 29444993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient design for estimation of median lethal dose and quantal dose-response curves.
    Kalish LA
    Biometrics; 1990 Sep; 46(3):737-48. PubMed ID: 2242412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Lack-of-Fit Assessment as a System Suitability Test for Potency Assays.
    Li R; Cai W; Zocher M
    PDA J Pharm Sci Technol; 2017; 71(5):368-378. PubMed ID: 28624777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model Selection and Estimation with Quantal-Response Data in Benchmark Risk Assessment.
    Peña EA; Wu W; Piegorsch W; West RW; An L
    Risk Anal; 2017 Apr; 37(4):716-732. PubMed ID: 27322778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant information in bioassay and semi-parametric estimation.
    Kim PT; Lee CH
    Stat Med; 2005 May; 24(9):1421-33. PubMed ID: 15568193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new bioassay for the immunocytokine L19-IL2 for simultaneous analysis of both functional moieties.
    Winter J; Barbin K; Bacci C; Bunte T
    J Pharm Biomed Anal; 2011 Jan; 54(1):81-6. PubMed ID: 20828971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.